Global /United States /Healthcare /Drug Manufacturers - General /LSTA

Lisata Therapeutics, Inc.

LSTA

• NASDAQ: LSTA • Delayed

3.23USD 0.9%

As of 13 June 2026, Lisata Therapeutics, Inc. has a market cap of $29.17M USD, ranking #34431 globally and #4801 in the United States. It ranks #3104 in the Healthcare sector, and #1054 in the Drug Manufacturers - General industry.

Global Rank

34431

Country Rank

4801

Sector Rank

3104

Industry Rank

1054

Key Stats

Market Cap

$29.17MUSD

Enterprise Value

$12.95MUSD

Revenue (TTM)

$170.0KUSD

EBITDA (TTM)

-$18.06MUSD

Net Income (TTM)

-$16.59MUSD

PS Ratio

170.0

PB Ratio

1.9

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

David Mazzo open_in_new

Employees

Founded

1980

Website

lisata.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.9%	-1.9%	-38%	-32%	12%	68%	23%	-4%	-87%

News

LSTA Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	LSTA Lisata Therapeutics Inc ISIN: US1280583022 Shares Out.: Shares Outstanding: 9.106M¹ Shares Float: 7.406M² TV: TradingView: NASDAQ: LSTA SA: Stock Analysis: NASDAQ: LSTA YF: Yahoo Finance: LSTA GF: Google Finance: NASDAQ: LSTA NQ: NASDAQ: LSTA BA: Barron's: LSTA MS: Morningstar: XNAS: LSTA	3.23 USD	TV: TradingView: NASDAQ: LSTA SA: Stock Analysis: NASDAQ: LSTA YF: Yahoo Finance: LSTA GF: Google Finance: NASDAQ: LSTA NQ: NASDAQ: LSTA BA: Barron's: LSTA MS: Morningstar: XNAS: LSTA
London Stock Exchange (LSE / LON) MIC: XLON	0HS8 Lisata Therapeutics Inc ISIN: US1280583022 TV: TradingView: LSE: 0HS8 SA: Stock Analysis: LON: 0HS8 YF: Yahoo Finance: 0HS8.L GF: Google Finance: LON: 0HS8 BA: Barron's: 0HS8 MS: Morningstar: XLON: 0HS8	3.12 USD	TV: TradingView: LSE: 0HS8 SA: Stock Analysis: LON: 0HS8 YF: Yahoo Finance: 0HS8.L GF: Google Finance: LON: 0HS8 BA: Barron's: 0HS8 MS: Morningstar: XLON: 0HS8

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 3M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 2M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 1M%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 939K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 512K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 403K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 1M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 990K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 941K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 623K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 377K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 372K%	14.6	United Kingdom

chevron_leftBack